176 related articles for article (PubMed ID: 12073798)
1. [Medication of the month. Rosiglitazone (Avandia)].
Scheen AJ
Rev Med Liege; 2002 Apr; 57(4):236-9. PubMed ID: 12073798
[TBL] [Abstract][Full Text] [Related]
2. Pioglitazone and rosiglitazone for diabetes.
Drug Ther Bull; 2001 Sep; 39(9):65-8. PubMed ID: 11586802
[TBL] [Abstract][Full Text] [Related]
3. Repaglinide : a pharmacoeconomic review of its use in type 2 diabetes mellitus.
Plosker GL; Figgitt DP
Pharmacoeconomics; 2004; 22(6):389-411. PubMed ID: 15099124
[TBL] [Abstract][Full Text] [Related]
4. Promising new approaches.
Reasner CA
Diabetes Obes Metab; 1999 May; 1 Suppl 1():S41-8. PubMed ID: 11220287
[TBL] [Abstract][Full Text] [Related]
5. Rosiglitazone.
Balfour JA; Plosker GL
Drugs; 1999 Jun; 57(6):921-30; discussion 931-2. PubMed ID: 10400405
[TBL] [Abstract][Full Text] [Related]
6. After avandia: the use of antidiabetic drugs in patients with heart failure.
Khalaf KI; Taegtmeyer H
Tex Heart Inst J; 2012; 39(2):174-8. PubMed ID: 22740727
[TBL] [Abstract][Full Text] [Related]
7. Rosiglitazone: a review of its use in the management of type 2 diabetes mellitus.
Wagstaff AJ; Goa KL
Drugs; 2002; 62(12):1805-37. PubMed ID: 12149047
[TBL] [Abstract][Full Text] [Related]
8. Pioglitazone, rosiglitazone, and rosiglitazone + metformin: new drugs. Glitazone + oral antidiabetic combination: inadequately evaluated.
Prescrire Int; 2005 Aug; 14(78):133-9. PubMed ID: 16106595
[TBL] [Abstract][Full Text] [Related]
9. Metabolic and additional vascular effects of thiazolidinediones.
Martens FM; Visseren FL; Lemay J; de Koning EJ; Rabelink TJ
Drugs; 2002; 62(10):1463-80. PubMed ID: 12093315
[TBL] [Abstract][Full Text] [Related]
10. The "glitazones": rosiglitazone and pioglitazone.
Papoushek C
J Obstet Gynaecol Can; 2003 Oct; 25(10):853-7. PubMed ID: 14532954
[TBL] [Abstract][Full Text] [Related]
11. Hepatotoxicity with thiazolidinediones: is it a class effect?
Scheen AJ
Drug Saf; 2001; 24(12):873-88. PubMed ID: 11735645
[TBL] [Abstract][Full Text] [Related]
12. [Diabetes therapy related to etiology. Indications, uses and side effects of new insulin sensitizers].
Ludvik B
MMW Fortschr Med; 2000 Jul; 142(28-29):27-8. PubMed ID: 10959156
[TBL] [Abstract][Full Text] [Related]
13. [A case report. Rosiglitazone treatment was highly effective yet had to be terminated].
Ridderstråle M; Groop L
Lakartidningen; 2002 Jan; 99(5):407-10. PubMed ID: 11881246
[TBL] [Abstract][Full Text] [Related]
14. Oral antidiabetic agents: current role in type 2 diabetes mellitus.
Krentz AJ; Bailey CJ
Drugs; 2005; 65(3):385-411. PubMed ID: 15669880
[TBL] [Abstract][Full Text] [Related]
15. Troglitazone: a review of its use in the management of type 2 diabetes mellitus.
Plosker GL; Faulds D
Drugs; 1999 Mar; 57(3):409-38. PubMed ID: 10193691
[TBL] [Abstract][Full Text] [Related]
16. Combined thiazolidinedione-insulin therapy: should we be concerned about safety?
Scheen AJ
Drug Saf; 2004; 27(12):841-56. PubMed ID: 15366973
[TBL] [Abstract][Full Text] [Related]
17. [Rosiglitazone (BRL-49653)].
Kameda N; Okuya S; Oka Y
Nihon Rinsho; 2000 Feb; 58(2):401-4. PubMed ID: 10707565
[TBL] [Abstract][Full Text] [Related]
18. Glitazones: clinical effects and molecular mechanisms.
Stumvoll M; Häring HU
Ann Med; 2002; 34(3):217-24. PubMed ID: 12173692
[TBL] [Abstract][Full Text] [Related]
19. Rosiglitazone.
Goldstein BJ
Int J Clin Pract; 2000 Jun; 54(5):333-7. PubMed ID: 10954962
[TBL] [Abstract][Full Text] [Related]
20. [The thiazolidinedione derivates: a new class of oral blood glucose lowering agents].
Jazet IM; Meinders AE
Ned Tijdschr Geneeskd; 2001 Aug; 145(32):1541-7. PubMed ID: 11525086
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
